Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD Study of Lingdolinurad in Healthy Volunteers
NCT03906006Phase 1Completed
- Sponsor
- Atom Therapeutics
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lingdolinurad in gout and hyperuricemia (4 cohorts), sponsored by Atom Therapeutics. Primary endpoints: Incidence of adverse events and Maximum tolerable dose. Started Oct 2018; status: completed.
02
Drugs
lingdolinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT03906006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906006.